Newscast – Page 158 – media

New genetic variants contribute to the risk of breast cancer in women, study reveals

A new study reveals seventy-two novel genetic variants that are responsible for breast cancer risk. Published in the journals Nature and Nature Genetics, of these 72 variants, 65 are common variants that predispose patients to breast cancer and a further seven variants predispose particularly to estrogen -receptor negative breast cancer - the subcategory of cases that do not respond to hormonal treatments.
- Source: news-medical
- 487
- October 25, 2017
breast cancer Researches
Alexion Wins Expanded Approval for Blockbuster Drug Soliris

Alexion Pharmaceuticals Inc. is set to secure even more revenue from its blockbuster drug Soliris, the most expensive drug in the world.
- Source: Biospace
- 821
- October 25, 2017
Alexion New Approvals Soliris
Researchers discover which brain region motivates behavior change

What's less established is which trigger in the brain causes people to break from a routine, especially when doing so poses potential risks.
- Source: Medicalxpress
- 521
- October 25, 2017
posterior cingulate cortex Researches
Scripps Florida Scientists Share $9 Million Grant to Develop Therapies that Target the Aging Process

Scientists from the Florida campus of The Scripps Research Institute (TSRI) and Albert Einstein College of Medicine will share in a $9 million grant from the National Institute on Aging, part of the National Institutes of Health, to study how individual genetic differences may form the basis for new therapeutic approaches that target the aging process itself rather than focusing on the treatment of individual diseases.
- Source: Scripps
- 477
- October 24, 2017
genetic Researches therapeutic
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation

Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection. Tafinlar in combination with Mekinist is in development to become the first adjuvant treatment specifically for melanoma patients with a BRAF V600 mutation.
- Source: novartis
- 719
- October 24, 2017
BTD FDA Melanoma New Approvals
Adult-onset ADHD may not exist, study suggests

More than 80 percent of people who have been diagnosed with attention deficit hyperactivity disorder(ADHD) in adulthood are unlikely to have the condition. This is the conclusion of a new study recently published in the American Journal of Psychiatry.
- Source: medicalnewstoday
- 576
- October 24, 2017
attention deficit hyperactivity disorder Researches
Cancer cells killed off with diabetes drug

Scientists may have found an innovative way to kill off cancer cells in acute myeloid leukemia(AML), all the while preserving and regenerating healthy red blood cells.
- Source: medicalnewstoday
- 763
- October 24, 2017
AML anemia cancer leukemia Researches
Johnson & Johnson Medical to buy German software firm Surgical Process Institute

Johnson & Johnson Group world wide chair Sandi Peterson said: “At Johnson & Johnson Medical Devices Companies, we are committed to broadening our portfolio of products and services to meet the changing needs of our customers around the world.
- Source: healthcareit.medicaldevices-business-review
- 492
- October 24, 2017
Johnson & Johnson
Researchers develop digestible sensors for monitoring the gastrointestinal tract

MIT’s researchers spend a lot of time thinking about digestible technology. In the past couple of years, scientists at the school have developed all sorts of swallowable devices, including a robot fashioned from pig parts designed to remove batteries. The school's Koch Institute in particular has focused on the space, looking at ways in which digestible sensors can be used to monitor things like drug intake.
- Source: techcrunch
- 654
- October 24, 2017
digestible sensor gastrointestinal tract MIT Researches
KU Leuven researchers identify new rapid response mechanism against bacterial infections

When bacteria enter our body, they kick-start a powerful immune response. But this chain of reactions doesn't fully account for our immediate responses. Researchers at KU Leuven, Belgium, show that so-called ion channels play a key role as 'first responders'.
- Source: news-medical
- 611
- October 24, 2017
bacteria immune infections

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.